Uncategorized

Originally published on 360DX.com by Greg Cima, Mar23, 2023. By Greg Cima NEW YORK – Backed by a mix of governmental contracts and VC funding, Irish startup Altratech is laying out a bold vision that its home-use microfluidic tests could replace PCR as the standard for molecular diagnostics. Unlike PCR's Read More

Hear from our CEO Tara Dalton as she presents our technology in the home diagnostics session on Tuesday 7th of March.Title of session: 'At-Home Next-Generation Molecular Detection with All-Synthetic PNA and CMOS'

Altratech's CTO, Tim Cummins, wins EIC 'Best-Pitch, E-Health' Award at EIC-CUF Healthcare Investor Day. Pictured with Cornelius Schmaltz, Ph.D, Head of Unit EIC Accelerator, EISMEA.

This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50122C00067

Dr Tara Dalton will be presenting Altratech's technology and assay at the World Home Diagnostics Summit in San Diego on November 30th.

At NextGenDx conference (Aug 2022), Altratech presented "Enabling Point-of-Care Diagnostics"

Altratech is developing a portable RNA kit, a device capable of diagnosing viruses such as HIV, Ebola and zika without the need for a lab.

At NextGenDx conference (Aug 2020), Altratech presented “Novel Techniques for POC Disease Monitoring Utilizing Programmable Molecular Velcro” These advanced PNA probes were co-developed by Altratech and NIH, and jointly filed in a US patent disclosure

MedTech Innovator Selects 50 Best-in-Class Startups for 2019 Showcase and Accelerator

PNA probes have different design rules to other oligomer probes. Altratech has developed a PNA-probe design tool “ROCAP” and launched it today at Medica 2018. It is in beta use at Altratech, at partners, and at NIH in US